# Evaluation of PSMA-PET and mpMRI in High-risk Prostate Cancer - Using Histopathologic Validation

> **NCT06565247** · PHASE3 · RECRUITING · sponsor: **Region Västerbotten** · enrollment: 60 (estimated)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** [18F]PSMA-PET
- **DEVICE:** MRI sequences optimized for prostate cancer examinations

## Key facts

- **NCT ID:** NCT06565247
- **Lead sponsor:** Region Västerbotten
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-10-14
- **Primary completion:** 2026-12
- **Final completion:** 2031-12
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-03-04

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06565247

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06565247, "Evaluation of PSMA-PET and mpMRI in High-risk Prostate Cancer - Using Histopathologic Validation". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06565247. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*